NAGE
NASDAQ · Life Sciences Tools & Services
Niagen Bioscience Inc
$5.20
+0.07 (+1.36%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 101.74M | 89.34M | 128.15M | 119.93M | 113.70M |
| Net Income | 8.73M | 6.90M | 13.22M | 14.89M | 12.09M |
| EPS | — | — | — | — | — |
| Profit Margin | 8.6% | 8.2% | 10.3% | 12.4% | 10.6% |
| Rev Growth | +13.9% | +13.9% | +9.9% | +11.4% | +12.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 62.2K | 62.2K | 137.79M | 133.61M | 160.13M |
| Total Equity | 207.43M | 207.43M | 173.79M | 171.80M | 169.78M |
| D/E Ratio | 0.00 | 0.00 | 0.79 | 0.78 | 0.94 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 8.57M | 7.15M | 24.92M | 27.61M | 22.05M |
| Free Cash Flow | — | — | 18.94M | 17.96M | 17.42M |